Updated on 8 February 2013
RegeneRx gets Notice of Allowance from Chinese Patent Office
Singapore: RegeneRx Biopharmaceuticals has received a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease.
RegeneRx Biopharmaceuticals' claims also include uses for restoring heart tissue in those subjects. The patent will expire July 26, 2026.